Projet d'acquisition de Monsanto, enquête phase II au niveau européen : Bayer continuera de travailler de manière constructive avec la Commission Européenne

Ce 22 août 2017, Bayer a confirmé que la Commission Européenne avait lancé une enquête de phase II sur le projet d’acquisition de Monsanto par Bayer.

Bayer s'attendait à ce que la Commission lance à une nouvelle étude complémentaire du projet en raison de la taille et de la portée de la transaction. Bayer estime que le rapprochement proposé sera bénéfique à la fois pour les agriculteurs et les consommateurs.

Les 2 sociétés ont notifié cette transaction à la Commission le 30 juin 2017 et ont soumis leurs engagements le 31 juillet 2017.

Bayer continuera de travailler de manière étroite et constructive avec la Commission Européenne dans son enquête, en vue d'obtenir l'approbation de la transaction par la Commission d'ici la fin de cette année.

Bayer: Science For A Better Life, la science pour une vie meilleure.

Pour plus d’informations, nous vous invitons à consulter le site Advancing Together [en] ou le site de Bayer AG [en].

Forward-Looking Statements: Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto’s operations into those of Bayer; such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of the refinancing of the loans taken out for the transaction, the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company’s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended August 31, 2016 and Monsanto’s other filings with the SEC, which are available at http://www.sec.gov and on Monsanto’s website at www.monsanto.com; and other factors discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. Bayer and Monsanto assume no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date.